InVivo Therapeutics Holdings Corp.
One Kendall Square, Suite B14402
Cambridge, MA 02139
November 17, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | InVivo Therapeutics Holdings Corp. | |
| Registration Statement on Form S-1 | ||
| File No. 333-268256 | ||
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, InVivo Therapeutics Holdings Corp. hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-268256), so that it may become effective at 4:00 p.m. on November 21, 2022, or as soon thereafter as practicable.
[Remainder of Page Intentionally Left Blank]
| Very truly yours, | ||
| INVIVO THERAPEUTICS HOLDINGS CORP. | ||
| By: | /s/ Richard Toselli | |
| Name: Richard Toselli | ||
| Title: President and Chief Executive Officer | ||
Signature Page to Acceleration Request